Загрузка...
When Standard Therapy Fails in Breast Cancer: Current and Future Options for HER2-Positive Disease
The area of HER2-positive breast cancer is a rapidly changing field. The use of the humanized monoclonal antibody, trastuzumab, significantly improved the prognosis for patients with HER2-positive breast cancer, however, increasing knowledge regarding mechanisms of resistance to trastuzumab have com...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3920550/ https://ncbi.nlm.nih.gov/pubmed/24527366 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4172/2167-0870.1000129 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|